BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva

- February 6th, 2018

BioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware. As quoted in the press release: “We … Continued

BioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware.

As quoted in the press release:

“We are pleased to have resolved our BELBUCA lawsuit with Teva.  We believe that this settlement, together with our previously announced settlement of the lawsuit with Teva regarding BUNAVAIL®, provide additional certainty around our patent portfolio and the future potential for our two commercialized products,” said Scott Plesha, President of BioDelivery Sciences.  “Importantly, settling these lawsuits allows us to avoid future litigation costs and thus preserve capital resources.”

Click here to read the full press release.

Looking for great biotech companies?

 
Find new opportunities and valuable news in your free report
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *